h1B11-12 / ME Therap - LARVOL DELTA

ME THERAPEUTICS HOLDINGS INC. PROVIDES AN OVERVIEW AND UPDATE ON CURRENT RESEARCH AND DEVELOPMENT PROGRAMS (Canada Newswire) - "ME Therapeutics existing data has demonstrated that h1B11-12 binds and neutralizes human G-CSF both in vitro and in vivo (animal models)....This testing is planned to be carried out in order to de-risk future investigational new drug (IND)-enabling studies which require the use of h1B11-12 manufactured under good manufacturing practices (GMP) and for animal safety studies to be carried out under good laboratory practices (GLP), both of which are costly and time consuming....In November 2023, the Company successfully produced sufficient h1B11-12 to send to our contract testing partner, Bioduro-Sundia, for the planned NHP safety studies. The Company anticipates the first preliminary safety study to be initiated in the coming weeks with the final results to become available in early 2024."

Preclinical • Oncology